Gyre Therapeutics (GYRE) Operating Leases (2019 - 2026)
Gyre Therapeutics (GYRE) reported Operating Leases of $72000.0 for Q1 2026, down 90.77% year-over-year from $780000.0 in Q1 2025, and down 76.24% quarter-over-quarter from $303000.0 in Q4 2025.
Gyre Therapeutics (GYRE) Operating Leases (2019 - 2026) Analysis & Trends
Gyre Therapeutics (GYRE) has 8 years of Operating Leases data on file, last reported at $72000.0 in Q1 2026.
- Operating Leases for Q1 2026 came in at $72000.0, down 90.77% year-over-year; the trailing twelve-month figure through Mar 2026 was $72000.0 (down 90.77% YoY), and the FY2025 annual result was $303000.0, down 65.76% from the prior year.
- Operating Leases fell to $72000.0 in Q1 2026 per GYRE's latest filing, from $303000.0 in the prior quarter.
- Over five years, Operating Leases peaked at $1.3 million in Q2 2024 and troughed at $72000.0 in Q1 2026.
- A 5-year average of $567545.5 and a median of $539000.0 in 2025 frame the typical range for Operating Leases.
- The sharpest annual moves came in 2025 and 2026: Operating Leases soared 345.71% in 2025, then sank 90.77% in 2026.
- A 5-year view of Operating Leases shows it stood at $121000.0 in 2022, then soared by 64.46% to $199000.0 in 2023, then surged by 344.72% to $885000.0 in 2024, then tumbled by 65.76% to $303000.0 in 2025, then tumbled by 76.24% to $72000.0 in 2026.
- Business Quant data shows GYRE's Operating Leases at $72000.0 in Q1 2026, $303000.0 in Q4 2025, and $539000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Gyre Therapeutics | 554.75 Mn | 540.62 Mn | 8.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 72,000.00 |
| Dec 31, 2025 | 303,000.00 |
| Sep 30, 2025 | 539,000.00 |
| Jun 30, 2025 | 771,000.00 |
| Mar 31, 2025 | 780,000.00 |
| Dec 31, 2024 | 885,000.00 |
| Sep 30, 2024 | 1.10 Mn |
| Jun 30, 2024 | 1.30 Mn |
| Mar 31, 2024 | 175,000.00 |
| Dec 31, 2023 | 199,000.00 |
| Dec 31, 2022 | 121,000.00 |
| Dec 31, 2021 | 408,000.00 |
| Sep 30, 2021 | 550,000.00 |
| Jun 30, 2021 | 1.05 Mn |
| Mar 31, 2021 | 806,000.00 |
| Dec 31, 2020 | 981,000.00 |
| Sep 30, 2020 | 925,000.00 |
| Jun 30, 2020 | 1.06 Mn |
| Mar 31, 2020 | 1.19 Mn |
| Dec 31, 2019 | 1.32 Mn |